1Jemal A, Bray F, Center MM, et al. Global cancer statis- tics[J]. CA Cancer J Clin, 2011,61 (2) ~ 69-90.
2Halvorsen EC, Mahmoud SM, Bennewith KL. Emerging roles of regulatory T ceils in tumour progression and metastasis [J]. Cancer Metastasis Rev, 2014,33 (4) : 1025-1041.
3Feuerer M, Hill JA, Mathis D, et al. Foxp3+ regulatory T cells : differentiation, specification, subphenotypes [J ]. Nat Immunol, 2009,10(7) .. 689-695.
4Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin- 10-secreting type 1 regulatory T cells in rodents and hu- mans[J]. Immunol Rev,2006,212(1) ..28-50.
5Fontenot JD,Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells[J]. Nat Immunol,2003,4(4) .. 330-336.
6Trzonkowski P. CD4+ CD25+ T regulatory cells inhibitcytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction[Jl. Clin Immunol, 2004,52 (I) ..258-267.
7Schloesser HA, Theurieh SA, Holtick U, et al. Overco- ming tumor-mediated immunosuppression [J]- Immuno- therapy,2014,6(9) ..973-988.
8Li CH, Kuo WH, Chang WC, et al. Activation of regulato- ry T cells instigates functional down-regulation of cyto- toxic T lymphocytes in human breast cancer[J]. Immunol Res,2011,51(1) : 71-79.
9Thornton AM, Shevach EM. CD4+ CD25+ immunoregula- tory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production[J]. J Exp Med, 1998,188(2) : 287-296.
10Liu JT, Yue J, Ren XB, et al. Measurement of CD4+ CD25+ T cells in breast cancer patients and its significance[Jr]. Zhong- hua Zhong Liu Za Zhi,2005,27(7) ..423-425.
2Yang Q, Liu X, Liu M, et al. Ulinastatin - mediated protection a-gainst zymosan -induced multiple organ dysfunction in rats[J].Biologi-cals, 2010,38 (5 ):552-556.
3Li YM,Chen H,Li X,et al.A new immunomodulatory therapy forsevere sepsis: Ulinastatin Plus Thymosin (alpha) 1 [J].J Intensive CareMed,2009,24(l):47-53.
4Oka N, Okumura Y, Kanayama HO,et al.Amiloride and urinarytrypsin inhibitor inhibit urothelial cancer invasion[J].Eur Urol,2003,44(6):737-741.
5HirabayasKi N, Tanimura H, Yamaue H.Nitrite/nitrate oxide andcytokines changes in patients with surgical stress[J].Dig Dis Sci, 2005,50(5):893-897.
6Zhao X,Sun X,Gao F,et al.Effects of ulinastatin and docataxel onbreast tumor growth and expression of IL-6,IL-8,and TNF-alpha[J]JExp Clin Cancer Res,2011,30(1) :22.
7Zhong B, Shen H,Sun X,et al.Additive effects of ulinastatin anddocetaxel on growth of breast cancer xenograft in nude mice and ex-pression of PGE2, IL -10, and IL-2 in primary breast cancer cells [J].Cancer Biother Radiopharm,2012,27(4) :252-258.
8Luo J,Sun X,Gao F,et al.Effects of ulinastatin and docetaxel onbreast cancer invasion and expression of uPA, uPAR and ERK[J].J ExpClin Cancer Res,2011(30) :71.
9Lugade AA,Sorensen EW,Gerber SA.et al.Radiation-induced IFN-gamma production within the tumor microenvironment influences antitu-mor immunity[J].J Immunol,2008,180(5):3132-3139.
10Moria M,Benotmanea MA,Tironea I,et al.Transcriptional responseto ionizing radiation in lymphocyte subsets[J].Cell Mol Life Sci Res,2005,62(13)=1489-1501.
